Curofy
FDA panel votes down expanded ezetimibe indications
An advisory committee of the Food and Drug Administration, unconvinced of a clinically meaningful effect based on the IMPROVE-IT trial, voted against approving an expanded indication for ezetimibe (Zetia) in combination with simvastatin (Zocor).
See this content immediately after install